Guidelines for the Compilation of a Product Dossier for Submission in the Assessment Procedure for New and Multi-Source (Generic) Products Used in the Treatment of Malaria
(11 pages)
Table of Contents
View the documentSection 1. Details of the product
View the documentSection 2. Regulatory situation in other countries
Open this folder and view contentsSection 3. Active pharmaceutical ingredient (s) (API)
Close this folderSection 4. Finished product
View the documentSection 4.1 Formulation
View the documentSection 4.2. Sites of manufacture
View the documentSection 4.3 Manufacturing procedure
View the documentSection 4.4 Specifications for excipients
View the documentSection 4.5 Specifications for the finished product
View the documentSection 4.6 Container/closure system(s) and other packaging
View the documentSection 4.7 Stability testing
View the documentSection 4.8 Container labelling
View the documentSection 4.9 Product information
View the documentSection 4.10 Patient information and package inserts
View the documentSection 4.11 Justification for any differences to the product in the country or countries issuing the submitted WHO-type certificate(s)6
Open this folder and view contentsSection 5. Efficacy and safety
 

Section 4.11 Justification for any differences to the product in the country or countries issuing the submitted WHO-type certificate(s)6

6 The WHO type certificate of a Pharmaceutical Product refers to the certificate issued by the international drug regulatory authority. Further information, and the full text of the WHO document "Guidelines on the implementation of the WHO certification scheme on the quality of pharmaceutical products moving in international commerce" can be found in the website http://www.who.int/medicines/


When there are differences between the product for which this application is submitted and that marketed in the country or countries which provided WHO-type certificate(s), provide arguments and/or data to support the applicability of the certificates despite the differences. Depending on the case, it may be necessary to provide validation data for differences in site of manufacture, specifications, formulation, etc.

Note that only minor differences are likely to be acceptable. Differences in container labelling need not normally be justified.

 

to previous section to next section
 

Last updated: May 3, 2013